|
Diabetes
|
0.010 |
Biomarker
|
disease |
BEFREE |
ΔIAFA was significantly associated with remission to NGT (multiple-adjusted odd ratio [1-SD decrease] 1.93, 95% CI 1.10-3.36) independent of IAFA, ASFA, ΔASFA, IGI, HOMA-IR, age, sex, and family history of diabetes.
|
29859271 |
2018 |
|
Diabetes Mellitus
|
0.010 |
Biomarker
|
group |
BEFREE |
ΔIAFA was significantly associated with remission to NGT (multiple-adjusted odd ratio [1-SD decrease] 1.93, 95% CI 1.10-3.36) independent of IAFA, ASFA, ΔASFA, IGI, HOMA-IR, age, sex, and family history of diabetes.
|
29859271 |
2018 |
|
Precursor B-cell lymphoblastic leukemia
|
0.030 |
Biomarker
|
disease |
BEFREE |
Unlike those of the mouse system, the pre-B-specific genes VpreB and lambda-like do not belong to the same transcriptional unit.
|
1903358 |
1991 |
|
Autoimmune Diseases
|
0.020 |
GeneticVariation
|
group |
BEFREE |
To the best of our knowledge, this is the first evidence showing the association between a low copy number of the VPREB1 gene and RA, and this may help understanding the pathogenesis of RA and other autoimmune disorders.
|
21144590 |
2011 |
|
Rheumatoid Arthritis
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
To the best of our knowledge, this is the first evidence showing the association between a low copy number of the VPREB1 gene and RA, and this may help understanding the pathogenesis of RA and other autoimmune disorders.
|
21144590 |
2011 |
|
Lupus Erythematosus, Systemic
|
0.020 |
Biomarker
|
disease |
BEFREE |
These results indicate that RAG expression is up-regulated in peripheral IgD+ and VpreB+ B cells of patients with active SLE.
|
12115231 |
2002 |
|
Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
These data show that VpreB RNA expression is a marker of the malignant forms of precursor B cells, and that it appears at least as early as cytoplasmic CD22 and CD19 in tumors of the B-cell lineage.
|
1884024 |
1991 |
|
Gestational Diabetes
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
There were no significant differences in gestational week and levels of HbA1c at diagnosis, levels of IGI and ISSI-2 between T-GDM and S-GDM (median, 20 weeks vs. 17 weeks, 5.0% vs. 5.2%, 0.58 vs. 0.71, 1.7 vs. 1.8, respectively).
|
31019153 |
2019 |
|
Myeloid Leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
The use of Burkitt lymphoma and myelogenous leukemia cell lines with translocations in the 22q11 region led to a refinement in the location according to the following order: cen----BCRL2, VpreB, IgV lambda 1----BCRL4, IgV lambda----IgC lambda----BCR----BCRL3, lambda-like----tel.
|
1903358 |
1991 |
|
Burkitt Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The use of Burkitt lymphoma and myelogenous leukemia cell lines with translocations in the 22q11 region led to a refinement in the location according to the following order: cen----BCRL2, VpreB, IgV lambda 1----BCRL4, IgV lambda----IgC lambda----BCR----BCRL3, lambda-like----tel.
|
1903358 |
1991 |
|
Adult Burkitt Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The use of Burkitt lymphoma and myelogenous leukemia cell lines with translocations in the 22q11 region led to a refinement in the location according to the following order: cen----BCRL2, VpreB, IgV lambda 1----BCRL4, IgV lambda----IgC lambda----BCR----BCRL3, lambda-like----tel.
|
1903358 |
1991 |
|
Childhood Burkitt Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The use of Burkitt lymphoma and myelogenous leukemia cell lines with translocations in the 22q11 region led to a refinement in the location according to the following order: cen----BCRL2, VpreB, IgV lambda 1----BCRL4, IgV lambda----IgC lambda----BCR----BCRL3, lambda-like----tel.
|
1903358 |
1991 |
|
Diabetic Retinopathy
|
0.010 |
Biomarker
|
disease |
BEFREE |
T2DM: Type 2 Diabetes Mellitus; HbA<sub>1C</sub>: Hemoglobin A<sub>1c</sub>; OHA: Oral Hypoglycemic Agents; STIT: Short-term Insulin Treatment; CSII: Continuous Subcutaneous Insulin Infusion; MDI: Multiple Daily Injections; PPG: Postprandial Plasma Glucose; FPG: Fasting Plasma Glucose; HOMA-b: Homeostasis Model Assessment of beta-cell function; TDD: Total Daily Insulin Dose; DI: Disposition Index; HOMA-IR: Homeostasis Model Assessment of Insulin Resistance; ROS: Reactive Oxygen Species; TNF: Tumor Necrosis Factor; GLP-1: Glucagon-like peptide-1; GIP: Glucose-dependent Insulinotropic Polypeptide; BMI: Body Mass Index; CV: Cardiovascular; DR: Diabetic Retinopathy; SU: Sulfonylurea; IGI: Insulinogenic Index.
|
30244600 |
2018 |
|
Rheumatoid Arthritis
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Studies of copy number variation in rheumatoid arthritis suggest that a reduced dosage of the VPREB1 gene is involved in disease pathogenesis.
|
24602812 |
2014 |
|
Common acute lymphoblastic leukemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Northern blot analysis of RNAs from 63 leukemia samples showed that VpreB RNA was present in malignancies of precursor B cells, the expression being a feature of both common acute lymphoblastic leukemia (ALL) (CD10+) and null ALL (CD10-).
|
1884024 |
1991 |
|
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.310 |
GeneticVariation
|
disease |
BEFREE |
None of the B-LBL cases showed abnormal, isolated VPREB1 deletion adjacent to IGL locus, which we identified in 25% of B-ALL.
|
27957801 |
2017 |
|
Acute lymphocytic leukemia
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
None of the B-LBL cases showed abnormal, isolated VPREB1 deletion adjacent to IGL locus, which we identified in 25% of B-ALL.
|
27957801 |
2017 |
|
Lymphoid leukemia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
None of the B-LBL cases showed abnormal, isolated VPREB1 deletion adjacent to IGL locus, which we identified in 25% of B-ALL.
|
27957801 |
2017 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.010 |
Biomarker
|
disease |
BEFREE |
NAT2 A803 allele seems to play a role in worsening the destiny of obese children carrying it, predisposing them to elevated-1HPG and IGT and then to a possible future type 2 diabetes mellitus throughout an impairment of pancreatic β-cellular insulin secretion as suggested by oDI and IGI reduction.
|
27481583 |
2017 |
|
Impaired glucose tolerance
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
NAT2 A803 allele seems to play a role in worsening the destiny of obese children carrying it, predisposing them to elevated-1HPG and IGT and then to a possible future type 2 diabetes mellitus throughout an impairment of pancreatic β-cellular insulin secretion as suggested by oDI and IGI reduction.
|
27481583 |
2017 |
|
Autoimmune arthritis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Instead, moderate VpreB expression partially protected mice from induced autoimmune arthritis.
|
25523463 |
2015 |
|
Down Syndrome
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
In total, 50% of DS ALL patients had ≥1 deletion in the B-cell development genes: PAX5 (12%), VPREB1 (18%) and IKZF1 (35%).
|
22441210 |
2012 |
|
Complete Trisomy 21 Syndrome
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
In total, 50% of DS ALL patients had ≥1 deletion in the B-cell development genes: PAX5 (12%), VPREB1 (18%) and IKZF1 (35%).
|
22441210 |
2012 |
|
Immune System Diseases
|
0.010 |
GeneticVariation
|
group |
BEFREE |
In humans, a copy number loss of 22q11.2, a region harboring the VPREB1 gene, has been suggested to be associated with several immunologic disorders, but there has been no study on the copy number variation (CNV) of the VPREB1 and its potential association with RA.
|
21144590 |
2011 |
|
Autoimmune Diseases
|
0.020 |
AlteredExpression
|
group |
BEFREE |
However, no autoantibody production was detectable in VpreB or λ5 transgenic mice and VpreB expression could not accelerate autoimmunity.
|
25523463 |
2015 |